secwatch.observer — SEC 8-K summary
======================================

Issuer:     INNOVATE Corp. (VATE)
CIK:        0001006837
Form:       8-K
Filed at:   2026-02-10T23:59:59+00:00
Accession:  0001006837-26-000005
Event type: other_material
Sentiment:  positive
Materiality: 0.55
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MediBeacon TGFR article named 2025 JASN Editors’ Choice; commercial rollout started Jan 2026
--------------------------------------------------------------------------------

- MediBeacon's transdermal GFR article selected as one of five 2025 Editors' Choice articles by JASN.
- TGFR System uses Lumitrace injection and transdermal sensor to measure kidney function at point of care.
- INNOVATE holds 44.7% equity interest in MediBeacon; commercialization began Jan 2026 in select academic centers.
- Initial clinical focus: heart failure monitoring, transplant evaluation, and oncology drug dosing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1006837/000100683726000005/0001006837-26-000005-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1006837/000100683726000005/hchc-20260210.htm
  HTML page:      https://secwatch.observer/filing/0001006837-26-000005

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer